Madeleine Duvic

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma
    M Duvic
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Arch Dermatol 137:581-93. 2001
  2. ncbi request reprint Adult Langerhans cell histiocytosis limited to the skin
    Asha Singh
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, Tex 77030, USA
    Dermatology 207:157-61. 2003
  3. pmc Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 122:2077-84. 2008
  4. ncbi request reprint Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 127:276-80. 2007
  5. ncbi request reprint Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Pharmacogenet Genomics 16:253-63. 2006
  6. ncbi request reprint Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:6532-9. 2007
  7. ncbi request reprint Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies
    Madeleine Duvic
    Department of Dermatology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 21:33-40. 2007
  8. ncbi request reprint Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Unit 1365, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 15:2526-32. 2006
  9. ncbi request reprint In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 97:1822-31. 2005
  10. pmc Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma
    Chunying Li
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Hum Mutat 29:1443-51. 2008

Detail Information

Publications104 found, 100 shown here

  1. ncbi request reprint Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma
    M Duvic
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Arch Dermatol 137:581-93. 2001
    ..To determine the safety and efficacy of oral bexarotene (Targretin capsules; Ligand Pharmaceuticals Incorporated, San Diego, Calif)...
  2. ncbi request reprint Adult Langerhans cell histiocytosis limited to the skin
    Asha Singh
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, Tex 77030, USA
    Dermatology 207:157-61. 2003
    ..While dermatological manifestations occur in as many as 50% of cases, disease limited to the skin is uncommon among reported cases of adult LCH...
  3. pmc Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 122:2077-84. 2008
    ..013) in modifying risk. Together, these findings suggest that VDR polymorphisms may directly affect or modify the risk associated with known melanoma risk factors. Larger, population-based studies are needed to replicate our findings...
  4. ncbi request reprint Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 127:276-80. 2007
    ..26; 95% CI, 1.00-1.59) genotypes, compared with the VDR-FokI FF genotype. In conclusion, genetic variants (i.e., TaqI t protective allele and FokI f risk allele) in VDR may alter risk of CM...
  5. ncbi request reprint Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Pharmacogenet Genomics 16:253-63. 2006
    ..In conclusion, genetic variants in the FAS and FASLG genes may contribute to the etiology of CMM in the general population, particularly in those with a low risk of sunlight-induced CMM...
  6. ncbi request reprint Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:6532-9. 2007
    ..To examine the role of suboptimal DNA repair capacity (DRC) for UV light-induced DNA damage in the development of nonmelanoma skin cancer (NMSC) and tumor progression...
  7. ncbi request reprint Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies
    Madeleine Duvic
    Department of Dermatology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 21:33-40. 2007
    ..These drugs, in combination with currently used therapies, may increase the number and combinations of therapies available for the treatment of this chronic condition to optimize long-lasting responses in CTCL...
  8. ncbi request reprint Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Unit 1365, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 15:2526-32. 2006
    ..We concluded that genetic variants of the XPD gene might serve as biomarkers for susceptibility to cutaneous melanoma...
  9. ncbi request reprint In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 97:1822-31. 2005
    ..However, an association between UV-induced chromosomal aberrations and risk of skin cancer in the general population has not been established...
  10. pmc Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma
    Chunying Li
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Hum Mutat 29:1443-51. 2008
    ..Therefore, these CASP8 and CASP10 polymorphisms may be biomarkers for susceptibility to CM...
  11. ncbi request reprint Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 27:1894-901. 2006
    ..Larger studies with more SNPs in the BER genes are needed to verify these findings...
  12. pmc Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
    Madeleine Duvic
    Department of Dermatology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 434, Houston, TX 77030 4409, USA
    Blood 109:31-9. 2007
    ..Vorinostat demonstrated activity in heavily pretreated patients with CTCL. The 400 mg daily regimen had the most favorable safety profile and is being further evaluated...
  13. pmc Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression
    Hongliang Liu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Melanoma Res 22:169-75. 2012
    ....
  14. ncbi request reprint Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study
    Chunying Li
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1570-8. 2007
    ..The authors hypothesized that selected functional single-nucleotide polymorphisms (SNPs) in the nNOS and iNOS genes are associated with the risk of CM...
  15. ncbi request reprint Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma
    Qingyi Wei
    Department of Epidemiology, Unit 189, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Natl Cancer Inst 95:308-15. 2003
    ....
  16. doi request reprint Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome
    Jonathan L Curry
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Cutan Pathol 38:295-7. 2011
    ..As far as we are aware, this is the first report of an Epstein-Barr virus-associated B-cell lymphoproliferative disorder, secondary to methotrexate therapy in a patient with mycosis fungoides/Sézary syndrome...
  17. ncbi request reprint 4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of nonmelanoma skin cancer: a case-control analysis
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 127:196-205. 2007
    ..However, there is a lack of correlation between UVB-induced b/c and 4-NQO-induced b/c in this study population. Therefore, these findings need to be verified by additional studies...
  18. ncbi request reprint Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study
    Narin Apisarnthanarax
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    J Am Acad Dermatol 50:600-7. 2004
    ..Topical skin-directed therapies are used to induce remissions in early-stage mycosis fungoides (MF). They are rarely curative, and responding patients are subject to frequent relapses, emphasizing the need for alternative therapies...
  19. ncbi request reprint Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:574-80. 2004
    ..The aim of the current study was to assess the toxicity, safety, and efficacy of IFN-alpha combined with isotretinoin in patients with advanced, refractory lymphoid malignancies...
  20. doi request reprint Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome
    Madeleine Duvic
    Department of Dermatology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Oncol 28:2365-72. 2010
    ..We studied the safety and efficacy of total skin electron beam with allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with cutaneous T-cell lymphoma (CTCL)...
  21. doi request reprint CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate
    Justin J Leitenberger
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Am Acad Dermatol 58:480-4. 2008
    ..Our observation highlights pralatrexate as a promising therapeutic option for hematodermic/plasmacytoid dendritic cell lymphoma/leukemias...
  22. ncbi request reprint CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma
    Rakhshandra Talpur
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4095, USA
    J Invest Dermatol 126:575-83. 2006
    ..These data suggest that high CD25 expression by IHC is associated with advanced CTCL and with clinical response to denileukin diftitox therapy...
  23. ncbi request reprint p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma
    Hongbing Shen
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 121:1510-4. 2003
    ..Further larger studies are needed to substantiate our findings...
  24. ncbi request reprint Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene
    Rakhshandra Talpur
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, 77030 4095, USA
    Clin Lymphoma Myeloma 6:488-92. 2006
    ..The purpose of this case report is to show the value of sequential combination therapy for improving overall response...
  25. doi request reprint Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling
    Chunlei Zhang
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 130:2110-9. 2010
    ..Our findings provide a mechanistic rationale for the potential use of curcumin as a therapeutic agent for patients with CTCL...
  26. pmc Genome-wide association study in alopecia areata implicates both innate and adaptive immunity
    Lynn Petukhova
    Department of Dermatology, Columbia University, New York, New York 10032, USA
    Nature 466:113-7. 2010
    ..We have defined the genetic underpinnings of AA, placing it within the context of shared pathways among autoimmune diseases, and implicating a novel disease mechanism, the upregulation of ULBP ligands, in triggering autoimmunity...
  27. ncbi request reprint The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells
    Chunlei Zhang
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 123:380-7. 2004
    ..Our findings suggest the rationale for further investigation of the clinical potential of CDDO, either alone or in combination with bexarotene for MF/SS patients...
  28. ncbi request reprint Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells
    Chunlei Zhang
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 128:2728-35. 2008
    ..Our findings underlie the therapeutic potential of avicin D in patients with SS...
  29. ncbi request reprint Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy
    Dan Jones
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:5587-94. 2004
    ..Using concurrent tumor samples from different anatomical sites, we compared expression of the therapeutic targets CD25 and CD30 in T-cell lymphoma (TCL)...
  30. doi request reprint Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides
    Putao Cen
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Acad Dermatol 58:382-6. 2008
    ..29), which is expressed on most carcinoma cells, is a soluble form of the glycoprotein MUC1. Measuring CA27.29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer...
  31. doi request reprint The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome
    Ming Yang Bi
    Baylor College of Medicine, Houston, Texas, USA
    J Am Acad Dermatol 64:53-63. 2011
    ..Alopecia can be a manifestation of mycosis fungoides (MF) and Sézary syndrome (SS), but the prevalence is unknown...
  32. pmc Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Eur J Cancer 47:107-15. 2011
    ..56 and 2.13, 95% CIs=1.02-2.38 and 1.22-3.70, respectively). These findings suggest that MMP1 promoter polymorphisms may individually or jointly play roles in the development of CM...
  33. doi request reprint Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
    Christiane Querfeld
    Department of Dermatology, Northwestern University, Chicago, IL 60611, USA
    Leuk Lymphoma 52:1474-80. 2011
    ..Enzastaurin was well tolerated with mostly grade 1-2 adverse events, mainly diarrhea and fatigue. There were two adverse event-related drug discontinuations with one possibly treatment-related...
  34. doi request reprint Clusterin expression correlates with stage and presence of large cells in mycosis fungoides
    Pranil Chandra
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 85, Houston, TX 77030, USA
    Am J Clin Pathol 131:511-5. 2009
    ..Clusterin expression was not specific for MF as it also was positive in 3 of 3 cases of LyP, 2 of 2 systemic ALCL cases involving skin, 7 of 16 cutaneous ALCLs, and 1 of 6 PTCLs...
  35. doi request reprint Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial
    Madeleine Duvic
    MD Anderson Cancer Center, Houston, TX, USA
    Eur J Cancer 49:386-94. 2013
    ..Here, panobinostat is studied in bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma (CTCL)...
  36. ncbi request reprint Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patients
    Steve A May
    Department of Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Am J Dermatopathol 29:62-7. 2007
    ..These cases are strikingly similar, and may represent an unusual clinicopathologic type of T-cell lymphoma that can hone to cutaneous and oral mucosal sites with a slowly progressive natural history...
  37. doi request reprint History of atopy or autoimmunity increases risk of alopecia areata
    Nazila Barahmani
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Acad Dermatol 61:581-91. 2009
    ..The association between a history of atopy or autoimmune diseases and risk of alopecia areata (AA) is not well established...
  38. ncbi request reprint Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
    Madeleine Duvic
    University of Texas MD Anderson Cancer Center, Department of Dermatology, Houston, TX 77030, USA
    Expert Opin Investig Drugs 16:1111-20. 2007
    ..The common side effects of vorinostat, which are similar in all studies, include gastrointestinal symptoms, fatigue and thrombocytopenia and the most common serious event was thrombosis...
  39. doi request reprint Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case series
    Kelley A Vidulich
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77027, USA
    Int J Dermatol 48:598-602. 2009
    ..Mycosis fungoides (MF)/Sézary syndrome (SS) patients are immunocompromised and thus may be susceptible to high-risk human papillomavirus (HPV) infections that are difficult to treat...
  40. ncbi request reprint Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Clin Lymphoma Myeloma 7:51-8. 2006
    ..The purpose of this study was to investigate safety and efficacy of gemcitabine monotherapy for cutaneous T-cell lymphoma (CTCL)...
  41. doi request reprint Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides
    Grace Sun
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Am Acad Dermatol 60:231-5. 2009
    ..Mycosis fungoides (MF), the most common cutaneous T-cell lymphoma, is most often seen in middle-aged to elderly men...
  42. ncbi request reprint Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma
    Chunlei Zhang
    Department of Dermatology, Division of Internal Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Dermatol Ther 16:322-30. 2003
    ..Identification of new receptor subtype-selective retinoids, combination of various receptor-selective retinoids or other agents, and a new drug delivery system may improve the clinical efficacy of retinoids in the future...
  43. ncbi request reprint Skin directed therapy for mycosis fungoides: a review
    Cindy Berthelot
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Drugs Dermatol 7:655-66. 2008
    ....
  44. ncbi request reprint Clonal heterogeneity in mycosis fungoides and its relationship to clinical course
    Francisco Vega
    Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 100:3369-73. 2002
    ..Demonstration of identical clonal GRs in multiple biopsy specimens at the time of diagnosis may provide prognostic information related to disease progression...
  45. pmc Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009
    Rakhshandra Talpur
    Departments of Dermatology and Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77027, USA
    Clin Cancer Res 18:5051-60. 2012
    ....
  46. doi request reprint Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor
    Jonathan L Curry
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Dermatopathol 35:125-8. 2013
    ..Furthermore, awareness of changes in tumor morphology after treatment with RAF inhibitors may be helpful in histologic evaluation of the spectrum of dermatologic toxicity, which may occur on targeted therapy...
  47. doi request reprint Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma
    Madeleine Duvic
    The University of Texas, MD Anderson Cancer Center, Department of Dermatology, Houston, TX 77030 4095, USA
    Leuk Lymphoma 54:514-9. 2013
    ..Three patients withdrew because of toxicity. This study showed that DD may provide clinically meaningful benefit in patients with CTCL who relapsed after initial response to DD...
  48. doi request reprint Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata
    Rakhshandra Talpur
    Division of Internal Medicine, Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    J Am Acad Dermatol 61:592.e1-9. 2009
    ..Alopecia areata, hair loss caused by perifollicular T-cell infiltrates, is refractory to therapy. Bexarotene, a retinoid X receptor is a selective retinoid, induces T-cell apoptosis...
  49. ncbi request reprint Mycosis fungoides: pathophysiology and emerging therapies
    Madeleine Duvic
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:S21-8. 2007
    ..The emergence of novel targeted therapies such as biologic agents, histone deacetylase inhibitors, and purine nucleoside phosphorylase inhibitors offers promise for more effective and safer treatment strategies for refractory CTCLs...
  50. ncbi request reprint Optimizing denileukin diftitox (Ontak) therapy
    Madeleine Duvic
    The University of Texas MD Anderson Cancer Center, Division of Internal Medicine, Department of Dermatology, 1515 Holcombe Blvd, Unit 1452, Houston, TX 77030, USA
    Future Oncol 4:457-69. 2008
    ....
  51. ncbi request reprint High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma
    Sean D Doherty
    Baylor College of Medicine, Houston, Texas, USA
    Melanoma Res 16:461-3. 2006
  52. ncbi request reprint Efficacy and safety of topical tazarotene: a review
    Rakhashandra Talpur
    University of Texas, MD Anderson Cancer Center, Department of Dermatology, Houston, Texas, USA
    Expert Opin Drug Metab Toxicol 5:195-210. 2009
    ..Tazarotene (Tazorac, Avage, Allergan, Inc., Irvine, CA, USA) is a synthetic retinoic acid receptor- betagamma topical retinoid approved for the treatment of plaque psoriasis and acne vulgaris...
  53. ncbi request reprint Optimizing bexarotene therapy for cutaneous T-cell lymphoma
    Rakhshandra Talpur
    Division of Internal Medicine, Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Am Acad Dermatol 47:672-84. 2002
    ..Statins (inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase) may modulate class II major histocompatibility class expression and T-cell responses...
  54. ncbi request reprint Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK)
    Rakhshandra Talpur
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Leuk Lymphoma 43:121-6. 2002
    ....
  55. ncbi request reprint Annular plaques: An unusual manifestation of graft-versus-host disease
    Laura J Alexander
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Dermatol Online J 18:4. 2012
    ..Treatment of these skin lesions with ultraviolet A1 (UVA1) phototherapy resulted in significant improvement...
  56. ncbi request reprint Interleukin-1 receptor antagonist allele 2 and familial alopecia areata
    Nazila Barahmani
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Invest Dermatol 118:335-7. 2002
    ..A borderline association was observed between IL-1RN and patchy alopecia areata but it was not statistically significant (p =0.06). We also observed an association between IL1-RN*1 allele and patchy alopecia areata (p =0.045)...
  57. ncbi request reprint A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories
    Marco Herling
    Department of Hematopathology, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 104:328-35. 2004
    ..Our results indicate that incorporation of additional criteria, such as TCL1 expression status and hematologic parameters, can assist in a more accurate classification...
  58. ncbi request reprint Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas
    Xiao Ni
    Department of Dermatology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 124:741-50. 2005
    ..Both bystander cytotoxicity and resistance to AICD are likely to contribute to the loss of cytotoxic anti-tumor CD8(+) T cells as well as the accumulation of malignant T cells in CTCL...
  59. ncbi request reprint Long-term control of mycosis fungoides of the hands with topical bexarotene
    Ted Lain
    Division of Internal Medical Specialties, Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Dermatol 42:238-41. 2003
    ..Patients with no prior therapy for mycosis fungoides responded at a higher rate (75%) than those with prior topical therapies...
  60. ncbi request reprint Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Cutan Med Surg 7:3-7. 2003
  61. ncbi request reprint Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas
    Apostolia Maria Tsimberidou
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Am Acad Dermatol 51:200-4. 2004
    ..Tumor necrosis factor (TNF)-alpha has been implicated in the pathogenesis of cutaneous T-cell lymphoma (CTCL)...
  62. doi request reprint Atypical histologic and immunohistochemical findings in melanocytic nevi after liquid nitrogen cryotherapy
    Adebowale J Adeniran
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Acad Dermatol 61:341-5. 2009
    ..Histologically, there was loss of maturation and aberrant HMB-45 expression. These features may pose a diagnostic dilemma, and highlight the importance of clinicopathologic correlation in arriving at the correct diagnosis...
  63. ncbi request reprint Primary and metastatic malignant tumors of the scalp: an update
    Heather M Richmond
    Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Am J Clin Dermatol 11:233-46. 2010
    ....
  64. ncbi request reprint Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
    Youn H Kim
    Department of Dermatology, Multidisciplinary Cutaneous Lymphoma Program, Stanford Cancer Center, Stanford, California 94305, USA
    J Am Acad Dermatol 63:975-83. 2010
    ..PF-3512676 (formerly CPG 7909) is a Toll-like receptor 9 agonist that is being investigated for treatment of patients with advanced cancer...
  65. ncbi request reprint Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox
    Kelley Vidulich
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 8:55-8. 2008
    ..We describe a patient with deep ulcers initially diagnosed as pyoderma gangrenosum, which was reclassified as CGD-TCL. Local radiation followed by weekly infusions of denileukin diftitox put the patient into remission...
  66. ncbi request reprint A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides
    Madeleine Duvic
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX, 77030, USA
    J Am Acad Dermatol 55:807-13. 2006
    ..Progression of mycosis fungoides is associated with Th(2) cytokines produced by a clonal proliferation of epidermotropic T-helper cells...
  67. ncbi request reprint Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)
    Madeleine Duvic
    Department of Dermatology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 2:222-8. 2002
    ..Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity...
  68. ncbi request reprint Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions
    Sean D Doherty
    Department of Dermatology, M D Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Arch Dermatol Res 298:353-6. 2006
    ..These findings indicate that abnormal IL-23 expression may play a role in the pathogenesis and progression of MF/SS...
  69. doi request reprint A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders
    Madeleine Duvic
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4003, USA
    Clin Cancer Res 15:6217-24. 2009
    ....
  70. ncbi request reprint Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel
    Ashley G Perna
    Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Clin Lymphoma 5:190-3. 2004
    ..However, the LyP relapsed and proved refractory to psoralen plus ultraviolet-A phototherapy, and was only temporarily and partially responsive to bexarotene and denileukin diftitox...
  71. ncbi request reprint Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides
    Farah Ghori
    Department of Dermatology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 434, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 91:2205-8. 2006
    ..Denileukin diftitox binds to the high-affinity IL-2 receptor on the cell surface, and it is internalized by endocytosis and enzymatically cleaved. The cytotoxic A-fragment of the toxin inhibits protein synthesis and causes cell death...
  72. ncbi request reprint Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1
    Parul Hazarika
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 64:7361-9. 2004
    ..Flot-2 binds to PAR-1, a known upstream mediator of major signal transduction pathways implicated in cell growth and metastasis, and may thereby influence tumor progression...
  73. ncbi request reprint Treatment of cutaneous T cell lymphoma: current status and future directions
    Narin Apisarnthanarax
    Division of Internal Medicine, Department of Dermatology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Clin Dermatol 3:193-215. 2002
    ..Further developments for CTCL may include more selective immunomodulatory agents, vaccines, and monoclonal antibodies...
  74. ncbi request reprint Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 100:342-9. 2004
    ..The goal of the current study was to assess the toxicity, safety, and efficacy of pentostatin in patients with T-cell lymphoid malignancies...
  75. ncbi request reprint DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma
    Zhigang Duan
    Departments of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 11:1142-3. 2002
  76. ncbi request reprint Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas
    Di Lu
    Department of Hematopathology, UT M D Anderson Cancer Center, Houston, TX 77030, USA
    J Cutan Pathol 29:465-72. 2002
    ....
  77. ncbi request reprint Alopecia areata registry: an overview
    Madeleine Duvic
    Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Investig Dermatol Symp Proc 8:219-21. 2003
    ..org. Samples of DNA, lymphoblast lines, and sera, as well as epidemiology and quality-of-life data, are being collected from well-characterized individuals, multiplex families, and sib pairs for future research studies and investigators...
  78. ncbi request reprint Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
    Nam H Dang
    MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 10:1513-8. 2003
    ..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications...
  79. ncbi request reprint Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma
    Madeleine Duvic
    Division of Internal Medicine, Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    J Am Acad Dermatol 49:35-49. 2003
    ....
  80. ncbi request reprint Coexistent psoriasis and lupus erythematosus treated with alefacept
    Cindy Berthelot
    Department of Internal Medicine, University of Texas Houston Health Science Center, Houston, TX, USA
    Am J Clin Dermatol 8:47-50. 2007
    ..The patient's arthritis flared after the second infusion of infliximab, which was discontinued. During treatment with alefacept, the patient's psoriasis improved markedly without exacerbation of his photosensitive SCLE lesions...
  81. ncbi request reprint Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action
    Chunlei Zhang
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1234-40. 2002
    ..We examined the effects of bexarotene on induction of apoptosis and expression of its cognate receptors in well-established CTCL cell lines (MJ, Hut78, and HH)...
  82. ncbi request reprint Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome
    Daniel J Lenihan
    Department of Cardiology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Blood 104:655-8. 2004
    ..The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further investigation...
  83. ncbi request reprint The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force
    Timothy G Berger
    Department of Dermatology, University of California, San Francisco, California, USA
    J Am Acad Dermatol 54:818-23. 2006
  84. ncbi request reprint Cutaneous manifestations of Hodgkin's disease
    Melissa Rubenstein
    Baylor College of Medicine and Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, 77030, USA
    Int J Dermatol 45:251-6. 2006
    ..The goal of this study was to define the spectrum of cutaneous manifestations of HD, as observed by the consulting dermatologist at a cancer center...
  85. ncbi request reprint Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action
    Chunlei Zhang
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 125:1045-52. 2005
    ..Our data suggest that selective induction of malignant T cell apoptosis and modulation of acetylated histones, p21(WAF1), bax, Stat6, and caspase-3 may underlie the therapeutic action of SAHA in CTCL patients...
  86. ncbi request reprint Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformis
    Jenny Vu
    Department of Dermatology, University of Texas MD Anderson Cancer Center and Medical School, Houston, Texas 77030 4009, USA
    Am J Clin Dermatol 8:307-10. 2007
    ..Our case is the second reported case of common variable immunodeficiency syndrome associated with EV...
  87. ncbi request reprint Vorinostat in cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Drugs Today (Barc) 43:585-99. 2007
    ..Vorinostat, in combination with other agents such as radiation therapy and chemotherapy, can have synergistic or additive effects in a variety of cancers in clinical trials...
  88. ncbi request reprint Photopheresis versus transimmunization?
    Madeleine Duvic
    MD Anderson Cancer Center, Department of Dermatology, Houston, TX 77030, USA
    Leuk Lymphoma 47:1449. 2006
  89. ncbi request reprint Multinodular cutaneous spread in neuroendocrine tumor of the breast : an unusual presentation
    Kelley A Vidulich
    M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Clin Dermatol 8:379-83. 2007
    ..The tumor was seen to be infiltrating the dermis. This is a unique case of a neuroendocrine tumor of the breast with cutaneous spread. The number of reported cases of neuroendocrine tumors with cutaneous involvement remains small...
  90. ncbi request reprint Mortality risk from squamous cell skin cancer
    Gary L Clayman
    Department of Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 23:759-65. 2005
    ..To identify nonmelanoma skin cancer patients with squamous cell carcinoma (SCC) who are at greatest risk of disease-specific mortality...
  91. ncbi request reprint Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application
    Madeleine Duvic
    Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 121:902-9. 2003
    ..This association suggests that reversal of TIG-3 expression may help to explain the mechanism of retinoid action in epidermal differentiation and chemoprevention...
  92. ncbi request reprint Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA
    Xiao Ni
    Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 128:2631-9. 2008
    ..These data support the concept of using tumor mRNA for a vaccine strategy that requires small amounts of tumor cells without need for specific antigens in patients with SzS...
  93. ncbi request reprint Cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Acad Dermatol 51:S43-5. 2004
  94. ncbi request reprint Primary Sézary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism
    A Hafeez Diwan
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 123:510-5. 2005
    ..Many cases will lack the epidermotropism usually seen in mycosis fungoides...
  95. ncbi request reprint Topical and systemic retinoid therapy for cutaneous T-cell lymphoma
    Werner Kempf
    Department of Dermatology, University Hospital, Gloriastrasse 31, CH 8091, Zurich, Switzerland
    Hematol Oncol Clin North Am 17:1405-19. 2003
    ..In addition, new agonists of RAR and RXR, either selective or pan agonists, will become available and will enlarge the spectrum of vitamin A analogs that have antitumoral properties...
  96. ncbi request reprint Multiple plaques on the hands and feet. Mycosis fungoides (MF) palmaris et plantaris (MFPP)
    Thomas J Lambert
    Texas Tech University School of Medicine, Lubbock, TX, USA
    Arch Dermatol 143:109-14. 2007
  97. ncbi request reprint Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy
    Cindy Berthelot
    University of Texas Medical School Southwestern, Dallas, 77030, USA
    Clin Lymphoma Myeloma 6:329-32. 2006
    ..Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab. The mechanisms and occurrence of lymphoma after immune response modifiers are discussed...
  98. ncbi request reprint Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
    Elise A Olsen
    Duke University, Durham, NC, USA
    J Clin Oncol 25:3109-15. 2007
    ....
  99. doi request reprint Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine
    Omar Awar
    Department of Internal Medicine, UCLA Medical Center, Los Angeles, CA 90024, USA
    Oncology 73:130-5. 2007
    ....
  100. ncbi request reprint Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series
    Matt Morgan
    The Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 43:1297-302. 2002
    ..This retrospective case series is the first study ever to report a relationship between serum cations and CTCL in humans...
  101. ncbi request reprint Human leukocyte antigen class II alleles are associated with risk of alopecia areata
    Nazila Barahmani
    J Invest Dermatol 128:240-3. 2008